|
|
||||||||
Center for Cardiovascular Sciences, Department of Medicine, Section of Cardiology, and Department of Physiology and Biophysics, University of Illinois, Chicago, Illinois 60612
Submitted 20 June 2003 ; accepted in final form 12 January 2004
Protein kinase C (PKC) modulates cardiomyocyte function by phosphorylation of intracellular targets including myofilament proteins. Data generated from studies on in vitro heart preparations indicate that PKC phosphorylation of troponin I (TnI), primarily via PKC-
, may slow the rates of cardiac contraction and relaxation (+dP/dt and dP/dt). To explore this issue in vivo, we employed transgenic mice [mutant TnI (mTnI) mice] in which the major PKC phosphorylation sites on cardiac TnI were mutated by alanine substitutions for Ser43 and Ser45 and studied in situ hemodynamics at baseline and increased inotropy. Hearts from mTnI mice exhibited increased contractility, as shown by a 30% greater +dP/dt and 18% greater dP/dt than FVB hearts, and had a negligible response to isoproterenol compared with FVB mice, in which +dP/dt increased by 33% and dP/dt increased by 26%. Treatment with phenylephrine and propranolol gave a similar result; FVB mouse hearts demonstrated a 20% increase in developed pressure, whereas mTnI mice showed no response. Back phosphorylation of TnI from mTnI hearts demonstrated that the mutation of the PKC sites was associated with an enhanced PKA-dependent phosphorylation independent of a change in basal cAMP levels. Our results demonstrate the important role that PKC-dependent phosphorylation of TnI has on the modulation of cardiac function under basal as well as augmented states and indicate interdependence of the phosphorylation sites of TnI in hearts beating in situ.
troponin; protein kinase C; contractility; mouse
This article has been cited by other articles:
![]() |
Z.-F. Lai, Y.-Z. Chen, L.-P. Feng, X.-M. Meng, J.-F. Ding, L.-Y. Wang, J. Ye, P. Li, X.-S. Cheng, Y. Kitamoto, et al. Overexpression of TNNI3K, a cardiac-specific MAP kinase, promotes P19CL6-derived cardiac myogenesis and prevents myocardial infarction-induced injury Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H708 - H716. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Samarel PICOT: A Multidomain Scaffolding Inhibitor of Hypertrophic Signal Transduction Circ. Res., March 28, 2008; 102(6): 625 - 627. [Full Text] [PDF] |
||||
![]() |
R. J. Belin, M. P. Sumandea, E. J. Allen, K. Schoenfelt, H. Wang, R. J. Solaro, and P. P. de Tombe Augmented Protein Kinase C-{alpha}-Induced Myofilament Protein Phosphorylation Contributes to Myofilament Dysfunction in Experimental Congestive Heart Failure Circ. Res., July 20, 2007; 101(2): 195 - 204. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Jeong, H. Cha, E. Kim, M. Kang, D. K. Yang, J. M. Kim, P. O. Yoon, J. G. Oh, O. Y. Bernecker, S. Sakata, et al. PICOT Inhibits Cardiac Hypertrophy and Enhances Ventricular Function and Cardiomyocyte Contractility Circ. Res., August 4, 2006; 99(3): 307 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. MacGowan, J. Rager, S. G. Shroff, and M. A. Mathier In vivo {alpha}-adrenergic responses and troponin I phosphorylation: anesthesia interactions J Appl Physiol, April 1, 2005; 98(4): 1163 - 1170. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |